Effectiveness of botulinum toxin infiltration in spasticity of the 1st toe in patients with neurological pathology

Clínica Integral del pie-Ana Sans0 个研究点目标入组 120 人开始时间: 2021年6月14日最近更新: 2021年7月5日

适应症

试验速览

暂无简介。

•Neurological patients aged 18 to 80 years
•Patients with stroke, parkinson's or multiple sclerosis, who present spasticity of the 1st toe.
•Spasticity of the 1st toe, pain and gait instability.
•Hyperextension of the 1st finger, causing inability to put on shoes, in neurological patients.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 60
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 60

•Skin ulcers
•In pregnancy and lactation the use is contraindicated.
•Minor patients and those patients who do not have the authorization of a family member or guardian.
•Individuals with known hypersensitivity to botulinum toxin type A or to any of the excipients of the formulation.
•In case of infection at the proposed injection site (s).
•Eaton Lambert Syndrome patients.
•Patients with severe dysphagia or respiratory compromise.
•Patients with myasthenia gravis.

发起方

Clínica Integral del pie-Ana Sans